Home     Font Size: 1  2  3    Send to a Friend       search

2006 News Archive

Monoclonal Antibody, MORAb-009, Receives FDA Orphan Drug Designation for the Indication of Pancreatic Cancer

November 7, 2006

Exton, Pa., November 7, 2006 - Morphotek® Inc., a privately held biopharmaceutical company focused on the discovery and development of...

+ Read the Article

Morphotek Selected as One of the Region’s Top Three Fastest Growing Companies by Philadelphia 100®

November 1, 2006

Exton-based Biopharmaceutical Company Recognized for Innovative Product Pipeline Exton, PA, November 1, 2006 - Morphotek®...

+ Read the Article

Morphotek Raises $40 Million to Advance its Antibody Pipeline

October 12, 2006

Exton, PA, October 12, 2006 -- Morphotek® Inc., a privately held biopharmaceutical company focused on the discovery and development of...

+ Read the Article

European Patent Office Grants Morphotek Two Technology Patents

August 30, 2006

Exton , PA , August 30, 2006 -- Morphotek ® announced today that the European Patent Office has given...

+ Read the Article

Morphotek Announces Orphan Drug Status Granted for MORAb-003, a Monoclonal Antibody for the Treatment of Ovarian Cancer

June 22, 2006

Exton, PA, June 21, 2006- Morphotek, Inc. announced today that the United States Food and Drug Administration has granted Orphan Drug Status to...

+ Read the Article

Morphotek Announces Initiation of Phase II Clinical Studies for MORAb-003 in Ovarian Cancer.

June 8, 2006

Exton, PA - June 8, 2006- Morphotek, Inc. today announced initiation of Phase II efficacy studies in major cancer centers worldwide for its...

+ Read the Article

Morphotek Announces Three Presentations on its Lead Therapeutic Candidates MORAb-003 and MORAb-009 at the 2006 American Society of Clinical Oncology Meeting

May 17, 2006

Exton, PA - May 17, 2006 - Morphotek, Inc., a biopharmaceutical company, today announced that it has two presentations on its lead monoclonal...

+ Read the Article

Morphotek Announces Scientific Publications Describing its Human Antibody Technology and the Biological Role of a Neovascular Therapeutic Target Antigen

April 5, 2006

Exton-PA-April 3, 2006 - Morphotek Inc. today announced scientific publications in the February 28th and March 7th issues of the journal The...

+ Read the Article

Morphotek Announces Appointments and Promotions to Management Team

March 14, 2006

Exton, PA, March 13, 2006 -- Morphotek®, Inc. announced today the appointment of Robert Radie as Chief Business Officer and the...

+ Read the Article

Morphotek Announces FDA Acceptance of the IND for MORAb-009, a Monoclonal Antibody for the Treatment of Mesothelin-Expressing Cancers

February 13, 2006

Exton, PA., February 13, 2006 - Morphotek, Inc. today announced that the United States Food and Drug Administration (FDA) cleared its...

+ Read the Article

Go to Page: 1 2

Results per page   10  25  50